EPRX — EUPRAXIA PHARMACEUTICALS INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1581178 ·
British Columbia, Canada
Last close
$6.62
Market Cap
$437.41M
52W High
$9.32
52W Low
$5.63
ADV30
663,207
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -16,164,032 | -15,241,731 | 134,563,114 | 75,176,617 | 13,517,770 |
| Jun 2026 | 0 | — | -18,103,173 | -14,486,955 | 139,907,536 | 52,426,167 | 10,233,774 |
| Mar 2026 | 0 | — | -15,957,045 | -12,653,431 | 145,353,342 | 58,500,024 | 9,165,681 |
| Dec 2025 | 0 | — | -16,162,620 | -16,711,252 | 86,150,008 | 80,563,482 | 5,703,915 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-37,473,789
Investing CF
$-80,478,287
Financing CF
$151,448,193
CapEx
$-753,723
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.91
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-196,720,360
Inventory
—
Receivables
$688,219
ST Investments
$81,234,688
EBIT TTM
$-57,140,196
Pretax Income TTM
$-50,183,971
Interest Exp TTM
$0
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -38,434,039 | -38,576,143 | 86,150,008 | 5,703,915 | 82,041,436 | -28,552,218 |
| Dec 2024 | 0 | -27,003,411 | -25,502,536 | 34,942,355 | 3,103,386 | 33,404,803 | -29,994,491 |
| Dec 2023 | 0 | -27,847,229 | -28,220,796 | 20,266,229 | 19,373,903 | 2,216,207 | -20,748,619 |
| Dec 2022 | 0 | -17,617,452 | -18,489,629 | 19,122,249 | 11,914,395 | 7,786,525 | -14,395,201 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.04
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INDP | Indaptus Therapeutics, Inc. | $442.36M | $3.32 | — |
| EOLS | Evolus, Inc. | $442.80M | $6.69 | — |
| ARVN | ARVINAS, INC. | $446.61M | $6.82 | — |
| PHAT | Phathom Pharmaceuticals, Inc. | $447.10M | $5.50 | — |
| PRTA | PROTHENA CORP PUBLIC LTD CO | $424.15M | $8.26 | — |
News headlines (Yahoo Finance, 1h cache)
Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program
2026-11-10 21:16 · Yahoo
Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results
2026-11-10 21:01 · Yahoo
Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
2026-10-22 12:30 · Yahoo
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
2026-10-15 12:00 · Yahoo
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
2026-10-09 12:00 · Yahoo
Eupraxia Says Resolve Trial Updated Data Suggest Annual Dosing Possible in EoE Patients
2026-09-30 16:27 · Yahoo
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
2026-09-30 12:00 · Yahoo
Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice
2026-09-12 07:56 · Yahoo
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
2026-09-08 12:00 · Yahoo
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
2026-08-13 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.